Research progress of long non-coding RNA in colorectal cancer

doi:10.3877/cma.j.issn.2095-3224.2022.01.010

Abstract

Abstract:

Long non-coding RNA has been one of the hot topics in the field of tumor molecular mechanism research in recent ten years. It has been proved that it regulates gene expression in organism, which is closely related to the occurrence and development of tumor. Colorectal cancer is a kind of malignant tumor that seriously harms people's health. Studies have found that the expression of LncRNA is dysregulated in colorectal cancer, and the abnormally expressed LncRNA, as a key regulatory factor, can participate in a variety of biological processes, affecting the proliferation and apoptosis of tumor cells, invasion and metastasis, and the regulation of tumor drug resistance, providing a new idea for the clinical treatment of colorectal cancer. In addition, LncRNA can also be used as a potential biomarker for early diagnosis and prognosis assessment of colorectal cancer.

Key words: Colorectal neoplasms, Long non-coding RNA, Tumor progression

Yihao Zhu, Qingchao Tang. Research progress of long non-coding RNA in colorectal cancer[J]. Chinese Journal of Colorectal Diseases(Electronic Edition), 2022, 11(01): 65-69.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhjzcjbdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3224.2022.01.010

https://zhjzcjbdzzz.cma-cmc.com.cn/EN/Y2022/V11/I01/65

References 44

[1]	Djebali S, Davis CA, Merkel A, et al. Landscape of transcription in human cells[J]. Nature, 2012, 489(7414): 101-108.
[2]	Devaux Y, Zangrando J, Schroen B, et al. Long noncoding RNAs in cardiac development and ageing[J]. Nat Rev Cardiol, 2015, 12(7): 415-425.
[3]	Hall LL, Lawrence JB. XIST RNA and architecture of the inactive X chromosome: implications for the repeat genome[J]. Cold Spring Harb Symp Quant Biol, 2010, 75: 345-356.
[4]	Jégu T, Aeby E, Lee JT. The X chromosome in space[J]. Nat Rev Genet, 2017, 18(6): 377-389.
[5]	Zhang LF, Huynh KD, Lee JT. Perinucleolar targeting of the inactive X during S phase: evidence for a role in the maintenance of silencing[J]. Cell, 2007, 129(4): 693-706.
[6]	Zhu Y, Hu H, Yuan Z, et al. LncRNA NEAT1 remodels chromatin to promote the 5-Fu resistance by maintaining colorectal cancer stemness[J]. Cell Death Dis, 2020, 11(11): 962.
[7]	Zhao J, Sun BK, Erwin JA, et al. Polycomb proteins targeted by a short repeat RNA to the mouse X chromosome[J]. Science, 2008, 322(5902): 750-756.
[8]	Jain AK, Xi Y, McCarthy R, et al. LncPRESS1 is a p53-Regulated LncRNA that safeguards pluripotency by disrupting SIRT6-mediated de-acetylation of histone H3K56[J]. Mol Cell, 2016, 64(5): 967-981.
[9]	He W, Zhong G, Jiang N. et al. Long noncoding RNA BLACAT2 promotes bladder cancer-associated lymphangiogenesis and lymphatic metastasis[J]. J Clin Invest, 2018, 128(2): 861-875.
[10]	Tian T, Lv X, Pan G, et al. Long noncoding RNA MPRL promotes mitochondrial fission and cisplatin chemosensitivity via disruption of pre-miRNA processing[J]. Clin Cancer Res, 2019, 25(12): 3673-3688.
[11]	Lu C, Wei Y, Wang X. et al. DNA-methylation-mediated activating of lncRNA SNHG12 promotes temozolomide resistance in glioblastoma[J]. Mol Cancer, 2020, 19(1): 28.
[12]	Yuan JH, Liu XN, Wang TT. et al. The MBNL3 splicing factor promotes hepatocellular carcinoma by increasing PXN expression through the alternative splicing of lncRNA-PXN-AS1[J]. Nat Cell Biol, 2017, 19(7): 820-832.
[13]	Jain AK, Xi Y, McCarthy R, et al. LncPRESS1 is a p53-Regulated lncRNA that safeguards pluripotency by disrupting SIRT6-mediated de-acetylation of histone H3K56[J]. Mol Cell, 2016, 64(5): 967-981.
[14]	Liu B, Sun L, Liu Q, et al. A cytoplasmic NF-κB interacting long noncoding RNA blocks IκB phosphorylation and suppresses breast cancer metastasis[J]. Cancer Cell, 2015, 27(3): 370-381.
[15]	Huang JZ, Chen M, Chen D, et al. A peptide encoded by a putative lncRNA HOXB-AS3 suppresses colon cancer growth[J]. Mol Cell, 2017, 68(1): 171-184, e6.
[16]	Zhang M, Weng W, Zhang Q, et al. The lncRNA NEAT1 activates Wnt/β-catenin signaling and promotes colorectal cancer progression via interacting with DDX5[J]. J Hematol Oncol, 2018, 11(1): 113.
[17]	Cheng X, Xu X, Chen D, et al. Therapeutic potential of targeting the Wnt/β-catenin signaling pathway in colorectal cancer[J]. Biomed Pharmacother, 2019, 110: 473-481.
[18]	Luo Y, Chen JJ, Lv Q, et al. Long non-coding RNA NEAT1 promotes colorectal cancer progression by competitively binding miR-34a with SIRT1 and enhancing the Wnt/β-catenin signaling pathway[J]. Cancer Lett, 2019, 440-441: 11-22.
[19]	Peng W, Wang Z, Fan H. LncRNA NEAT1 impacts cell proliferation and apoptosis of colorectal cancer via regulation of Akt signaling[J]. Pathol Oncol Res, 2017, 23(3): 651-656.
[20]	Yang MH, Zhao L, Wang L, et al. Nuclear lncRNA HOXD-AS1 suppresses colorectal carcinoma growth and metastasis via inhibiting HOXD3-induced integrin-β3 transcriptional activating and MAPK/AKT signalling[J]. Mol Cancer, 2019, 18(1): 31.
[21]	Ghasemi F, Shafiee M, Banikazemi Z, et al. Curcumin inhibits NF-kB and Wnt/β-catenin pathways in cervical cancer cells[J]. Pathol Res Practice, 2019, 215: 152556.
[22]	Zhong ME, Chen Y, Zhang G, et al. LncRNA H19 regulates PI3K-Akt signal pathway by functioning as a ceRNA and predicts poor prognosis in colorectal cancer: integrative analysis of dysregulated ncRNA-associated ceRNA network[J]. Cancer Cell Int, 2019, 19: 148.
[23]	Sun C, Ma P, Wang Y, et al. KLF15 inhibits cell proliferation in gastric cancer cells via up-regulating CDKN1A/p21 and CDKN1C/p57 expression[J]. Dig Dis Sci, 2017, 62(6): 1518-1526.
[24]	Bykov VJN, Eriksson SE, Bianchi J, et al. Targeting mutant p53 for efficient cancer therapy[J]. Nat Rev Cancer, 2018, 18(2): 89-102.
[25]	Hientz K, Mohr A, Bhakta-Guha D, et al. The role of p53 in cancer drug resistance and targeted chemotherapy[J]. Oncotarget, 2017, 8(5): 8921-8946.
[26]	Thorenoor N, Faltejskova-Vychytilova P, Hombach S, et al. Long non-coding RNA ZFAS1 interacts with CDK1 and is involved in p53-dependent cell cycle control and apoptosis in colorectal cancer[J]. Oncotarget, 2016, 7(1): 622-637.
[27]	Liu F, Wang X, Liu H, et al. LncRNA BX357664 inhibits cell proliferation and invasion and promotes cell apoptosis in human colorectal cancer cells[J]. Oncol Lett, 2018, 15(6): 8237-8244.
[28]	Cui C, Zhai D, Cai L, et al. Long noncoding RNA HEIH promotes colorectal cancer tumorigenesis via counteracting miR-939‒mediated transcriptional repression of Bcl-xL[J]. Cancer Res Treat, 2018, 50(3): 992-1008.
[29]	Zhang W, Yuan W, Song J, et al. LncRna CPS1-IT1 suppresses cell proliferation, invasion and metastasis in colorectal cancer[J]. Cell Physiol Biochem, 2017, 44(2): 567-580.
[30]	Xue J, Liao L, Yin F, et al. LncRNA AB073614 induces epithelial- mesenchymal transition of colorectal cancer cells via regulating the JAK/STAT3 pathway[J]. Cancer Biomark, 2018, 21(4): 849-858.
[31]	Zhang H, Song Y, Yang C, et al. Overexpression of lncRNA TUSC7 reduces cell migration and invasion in colorectal cancer[J]. Oncol Rep, 2019, 41(6): 3386-3392.
[32]	Márquez-Jurado S, Díaz-Colunga J, das Neves RP, et al. Mitochondrial levels determine variability in cell death by modulating apoptotic gene expression[J]. Nat Commun, 2018, 9(1): 389.
[33]	Stintzing S, Modest DP, Rossius L, et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial[J]. The Lancet Oncology, 2016, 17(10): 1426-1434.
[34]	Longley DB, Allen WL, Johnston PG. Drug resistance, predictive markers and pharmacogenomics in colorectal cancer[J]. Biochim Biophys Acta, 2006, 1766(2): 184-196.
[35]	Wang M, Han D, Yuan Z, et al. Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy[J]. Cell Death Dis, 2018, 9(12): 1149.
[36]	Jiang X, Li Q, Zhang S, et al. Long noncoding RNA GIHCG induces cancer progression and chemoresistance and indicates poor prognosis in colorectal cancer[J]. Onco Targets Ther, 2019, 12: 1059-1070.
[37]	Dobreva G, Chahrour M, Dautzenberg M, et al. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation[J]. Cell, 2006, 125(5): 971-986.
[38]	Xu M, Xu X, Pan B, et al. LncRNA SATB2-AS1 inhibits tumor metastasis and affects the tumor immune cell microenvironment in colorectal cancer by regulating SATB2[J]. Mol Cancer, 2019, 18: 1-16.
[39]	Tang L, Li Q, Ge X, et al. LncRNA GAS5 inhibits progression of colorectal cancer by regulating M1/M2 macrophages polarization. AIP Conference Proceedings[J]. AIP Conference Proceedings, 2019, 2110(1): 020013.
[40]	Yu X, Yuan Z, Yang Z, et al. The novel long noncoding RNA u50535 promotes colorectal cancer growth and metastasis by regulating CCL20[J]. Cell Death Dis, 2018, 9(7): 751.
[41]	Liang ZX, Liu HS, Wang FW, et al. LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization[J]. Cell Death Dis, 2019, (10): 1-17.
[42]	Zhao W, Song M, Zhang J, et al. Combined identification of long non-coding RNA CCAT1 and HOTAIR in serum as an effective screening for colorectal carcinoma[J]. Int J Clin Exp Pathol, 2015, 8(11): 14131-14140.
[43]	Wan L, Kong J, Tang J, et al. HOTAIRM1 as a potential biomarker for diagnosis of colorectal cancer functions the role in the tumour suppressor[J]. J Cell Mol Med, 2016, (20): 2036-2044.
[44]	Ouyang W, Ren L, Liu G, et al. LncRNA MIR4435-2HG predicts poor prognosis in patients with colorectal cancer[J]. Peer J, 2019, 7: e6683.

Please choose a citation manager

Content to export